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Abstract: OBJECTIVES: To undertake a preliminary assessment of the potential for CT
measures of tumour heterogeneity to stratify risk of nodal metastasis in patients with
non-small cell lung cancer (NSCLC).
METHODS: Tumour heterogeneity in CT images from PET/CT examinations in 150
consecutive patients with NSCLC was assessed using CT texture analysis.  The short
axis diameter of the largest mediastinal node was also measured. 42 patients without
distant metastases subsequently had tumour nodal status confirmed by surgery (n=26)
or Endobronchial Ultrasound (EBUS); n=16). CTTA parameters and largest nodal
diameter were related to nodal status using the rank-correlation and the risk-ratio for
each nodal stage (>N0, >N1, >N2) was compared between patients categorised as
high and low risk by CTTA or nodal size. The most significant predictor of nodal status
was related to overall survival using Kaplan-Meier analysis.
RESULTS: N-stage was more significantly correlated with CTTA than nodal diameter
(Rs = -0.39, p = 0.011, Rs = -0.45, p=0.0025, Rs = -0.40, p=0.0091 for normalised SD,
normalised E and kurtosis respectively; Rs = -0.39, p = 0.042 for nodal diameter). The
presence of 2 or more high-risk CTTA values was the greatest risk-factor for
mediastinal metastasis (Risk-ratio: 11.0, 95% confidence interval 1.56 - 77.8,
p=0.0014) and was associated with significantly poorer overall survival (p=0.016).
CONCLUSION: CTTA in NSCLC is related to nodal status in patients without distant
metastases and has the potential to inform selection of investigative strategies for the
assessment of mediastinal malignancy.
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OBJECTIVES: To undertake a preliminary assessment of the potential for CT 
measures of tumour heterogeneity to stratify risk of nodal metastasis in patients 
with non-small cell lung cancer (NSCLC).  
 
METHODS: Tumour heterogeneity in CT images from PET/CT examinations in 150 
consecutive patients with NSCLC was assessed using CT texture analysis.  The short 
axis diameter of the largest mediastinal node was also measured. 42 patients 
without distant metastases subsequently had tumour nodal status confirmed by 
surgery (n=26) or Endobronchial Ultrasound (EBUS); n=16). CTTA parameters and 
largest nodal diameter were related to nodal status using the rank-correlation and 
the risk-ratio for each nodal stage (>N0, >N1, >N2) was compared between patients 
categorised as high and low risk by CTTA or nodal size. The most significant predictor 
of nodal status was related to overall survival using Kaplan-Meier analysis.  
 
RESULTS: N-stage was more significantly correlated with CTTA than nodal diameter 
(Rs = -0.39, p = 0.011, Rs = -0.45, p=0.0025, Rs = -0.40, p=0.0091 for normalised SD, 
normalised E and kurtosis respectively; Rs = -0.39, p = 0.042 for nodal diameter). The 
presence of 2 or more high-risk CTTA values was the greatest risk-factor for 
mediastinal metastasis (Risk-ratio: 11.0, 95% confidence interval 1.56 - 77.8, 
p=0.0014) and was associated with significantly poorer overall survival (p=0.016).  
 
Abstract
CONCLUSION: CTTA in NSCLC is related to nodal status in patients without distant 
metastases and has the potential to inform selection of investigative strategies for 
the assessment of mediastinal malignancy. 
 
KEY WORDS 
Non-small cell Lung Cancer, Positron-emission tomography, Computed Tomography 
Texture Analysis, Nodal metastasis  
 
CAN CT MEASURES OF TUMOUR HETEROGENEITY STRATIFY RISK FOR NODAL 1 
METASTASIS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER? 2 
 3 
INTRODUCTION:  4 
Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer in 5 
the Western World with a poor prognosis. Predictive factors of disease burden are 6 
required to help with decisions regarding options for clinical management. These 7 
circumstances are illustrated by the current clinical guidance for the management of 8 
NSCLC issued by the National Institute of Clinical Health and Excellence (NICE)(1). 9 
This guidance recommends different investigative strategies for the assessment of 10 
mediastinal disease according to probability of mediastinal malignancy based on 11 
nodal size as depicted by CT. For patients with a low probability of mediastinal 12 
malignancy (15%; lymph nodes < 10 mm maximum short axis on CT), the optimum 13 
strategy was determined to be staging with PET-CT alone. PET-CT, or endobronchial 14 
ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA), or endoscopic 15 
ultrasound (EUS)-guided fine needle aspiration, or non-ultrasound guided TBNA are 16 
recommended for patients with an intermediate probability of mediastinal 17 
malignancy (50%; lymph nodes between 10 and 20 mm maximum short axis on CT) 18 
whilst neck ultrasound with sampling of visible lymph nodes, or non-ultrasound 19 
guided TBNA should be offered to patients with a high probability of mediastinal 20 
malignancy (85%; lymph nodes > 20 mm maximum short axis on CT). New methods 21 
that can improve the risk stratification for mediastinal disease based on CT therefore 22 
Manuscript
have the potential to improve the selection of staging procedures for patients with 23 
NSCLC. 24 
CT texture analysis (CTTA) is emerging as a technique for derivation of prognostic 25 
biomarkers for patients with NSCLC and other tumours (2-5). CT texture analysis 26 
evaluates quantitatively the distribution of CT attenuation values within a tumour to 27 
determine its heterogeneity. Tumour heterogeneity has been shown to relate to 28 
tumour aggression and treatment response, with hypoxia, mutations in EGFR and 29 
KRAS genes, and ALK gene re-arrangements having been identified as potential 30 
biological correlates for CTTA values in NSCLC (2). Given the prognostic significance 31 
of CTTA and its associated biological characteristics, we hypothesize that CTTA can 32 
stratify risk for nodal metastatic disease in patients with NSCLC.   33 
 34 
METHOD: 35 
Study Design:  36 
A prospective observational study design was adopted, using patient data that was 37 
acquired as part of routine clinical care. Our local institutional review board had 38 
waived the requirement for individual consent. 39 
Patients:  40 
Imaging data was collected from 150 consecutive patients undergoing PET/CT for 41 
staging of NSCLC cancer. The study cohort of 42 patients comprised all those with no 42 
distant metastasis detected on PET/CT and subsequent confirmation of nodal status 43 
either at surgery (n=26) and or by EBUS with TBNA (n=16). Overall survival was 44 
determined from a median clinical follow-up period of 279 days (range: 59-437 45 
days). 46 
CT Imaging protocal and data analysis:  47 
Images were acquired using a Siemens mCT PET/CT system 120kV, automated tube 48 
modulation (Care dose) with reference tube current set at 80mAs, 5mm slices and 49 
collimation 1.2mm(Siemens, Erhlangen, Germany). Using TexRAD software 50 
(Feedback plc, Cambridge, UK), CTTA was performed on the low dose CT slice that 51 
displayed the largest cross sectional area of the tumour on soft tissue windows as 52 
described previously (2).  Definition of the tumour boundary was assisted with 53 
reference to the PET fused images and narrow CT windows (level 40HU, width 54 
150HU). Automated segmentation tools were used to optimise consistency in the 55 
analysis between operators were possible, for example where the tumour was 56 
surrounded by aerated lung. Where the lung tumour was in contact with other 57 
tissues such as the chest wall, mediastinum or consolidated lung, manual selection of 58 
the region of interest (ROI) was required along that border and the automated 59 
segmentation tool could be used on those areas where the tumour bordered 60 
aerated lung. Segmentation tools excluded areas of tumour cavitation seen on CT 61 
but were not used to exclude areas of necrosis/photopaenia seen on the PET fused 62 
images.  63 
Based on the filtration-histogram CTTA approach utilised by the CTTA software, 64 
tumour heterogeneity at a scale of 4mm was expressed as kurtosis, standard 65 
deviation (SD) and entropy (E). SD and E were both log-normalised to the tumour 66 
area determined by the number of pixels in the tumour ROI.  67 
The short-axis diameter of the largest mediastinal was also measured by a separate 68 
operator who was an accredited radiologist with more than 25 years of CT 69 
experience. 70 
Statistics 71 
The relationship between CTTA parameters and nodal status were determined using 72 
the rank-correlation and compared to the correlation found between N-stage and 73 
mediastinal nodal size. If a significant correlation was found, patients were 74 
categorised as high or low risk for nodal metastases using the median texture value 75 
for the study cohort. The risk for each nodal stage (>N0, >N1, >N2) was compared 76 
between high and low risk patients and expressed as the risk ratio (with 95% 77 
confidence limits), with comparison against the risk-ratios found for nodal size 78 
<10mm versus ≥ 10mm, using Fisher’s exact test to assess statistical significance. The 79 
most significant predictor of nodal status was related to overall survival using 80 
Kaplan-Meier analysis. 81 
 82 
RESULTS:  83 
42 patients NSCLC without distant metastases  went on to have nodal status 84 
confirmed either at surgery or EBUS with TBNA, the numbers of patients with N-85 
stages 0, 1, 2 and 3 were 26, 4, 8 and 4 respectively. 5 (11.9%) patients died during 86 
follow-up. 87 
N-stage was shown to correlate significantly with normalised SD, normalised E and 88 
kurtosis (Rs = -0.39, p = 0.011, Rs = -0.45, p=0.0025, Rs = 0.40, p=0.0091 89 
respectively). There was a weaker but statistically significant correlation between N-90 
stage and mediastinal nodal diameter (Rs = -0.39, p = 0.042).   CTTA values were 91 
categorised as high-risk for nodal metastases if below the median for normalised SD 92 
(5.66) and normalised E (0.777), or above the median for kurtosis (-0.295). 21 (50%) 93 
patients had 2 or more high-risk CTTA values. Example CT texture results from 94 
patients with high and low risk CTTA parameters are given in Figures 1 and 2. 95 
The greatest risk factors for node positive disease were log-normalised entropy and 96 
the presence of 2 or more high-risk CTTA values, each associated with a 4.3 greater 97 
likelihood of nodal metastases (p=0.0036, table 1). A mediastinal nodal diameter of ≥ 98 
10mm was a significant risk-factor for mediastinal malignancy (i.e. N stage 2 or 3) but 99 
its risk-ratio of 2.82 was exceeded by that found for all CTTA parameters. The 100 
presence of 2 or more high-risk CTTA values was the greatest risk-factor for 101 
mediastinal metastases, being associated with an 11-fold risk for mediastinal 102 
malignancy (p=0.0014) and significantly poorer overall survival (p=0.016, Figure 3). 103 
The only significant risk factor for N3- disease was mediastinal nodal size ≥10mm.  104 
 105 
DISCUSSION 106 
In this study we investigated the potential for CT measures of tumour heterogeneity to 107 
stratify risk of nodal disease in patients with NSCLC. CTTA parameters within the primary 108 
tumour were found to be superior predictors of nodal stage >0 and nodal >1 than the 109 
measurement of mediastinal nodal diameter as currently recommended by NICE. However, 110 
mediastinal nodal diameter was the best predictor for N-stage >2.  The finding that the 111 
presence of two or more high-risk CTTA values is not only associated with a greater risk of 112 
nodal stage >1 but also reduced survival, indicates that the presence nodal disease inferred 113 
by high-risk CTTA values is of clinical importance. 114 
CTTA has the potential to determine the optimum strategy for investigation of nodal disease 115 
more accurately than measurements of mediastinal nodal diameter as currently 116 
recommended by NICE. For example, the NICE guidance would recommend the nodal status 117 
for the patient with N2 disease illustrated in Figure 1 be determined by PET-CT alone. While 118 
PET CT is a non-invasive method in assessing for mediastinal nodal metastasis, its sensitivity 119 
and specificity of detecting mediastinal metastasis is only around 77% and 86% 120 
respectively(6). Furthermore the sensitivity of PET for detecting nodal metastasis is lower 121 
when the size of the lymph node is less than 10mm(7).  A PET/CT only strategy for this 122 
patient would have resulted in underestimation of disease status whereas the presence of 123 
high-risk CTTA parameters could feasibly have indicated the need for nodal sampling prior to 124 
surgery.  Similarly, due to the presence of an enlarged mediastinal node, the NICE guidance 125 
would recommend nodal sampling be considered for the patient with N0 disease illustrated 126 
in Figure 2 whereas this procedure may not have been considered necessary based on the 127 
absence of high-risk CTTA values. As the NICE strategies were optimised on the basis of cost-128 
effectiveness, CTTA therefore also has potential health economic benefits.  129 
The observation that tumours with increased metastatic potential exhibit greater genetic 130 
instability (8) provides a biological basis for a relationship between CT measures of tumour 131 
heterogeneity and nodal status. In the presence of genetic instability, the evolutionary 132 
dynamics of tumour development may result in the co-existence of genetically distinct sub-133 
clones within the same tumour (9). For these sub-clones to be detected by CT the genetic 134 
status of the sub-clone must correspond to one or more phenotypic features demonstrable 135 
by imaging. Furthermore, the spatial separation between sub-clones needs to be sufficiently 136 
large relative to the spatial resolution of CT (See Figure 4). The first requirement is shown to 137 
be met by radiogenomic studies demonstrating correlations between genomic aberrations 138 
and specific CT features in NSCLC and other tumours (5, 10-15). Spatial separation of sub-139 
clones has also been reported and may be sufficiently large to result in sampling error during 140 
image-guided biopsy (9). Although plausible, a direct connection between genomic 141 
instability, metastatic potential and CT measures of tumour heterogeneity remains to be 142 
demonstrated empirically.  143 
The main limitation of our study is the small size of our cohort of NSCLC patients without 144 
distant metastases for whom nodal status had been confirmed either at surgery or 145 
endobronchial biopsy.  Larger multi-centre studies are required to confirm our findings. To 146 
minimise potential bias, we have adopted median textures as the thresholds for the 147 
categorisation of high and low risk for nodal metastases. Larger studies would also allow 148 
optimisation of these threshold values through use of separate training and evaluation 149 
cohorts.  We have also adopted a single slice approach to assess for tumour heterogeneity 150 
which has the potential to miss regions of greater heterogeneity and hence under estimate 151 
the risk of nodal metastasis (3). The consistency of risk stratification by CTTA may also be 152 
potentially improved through automated CT ROI definition based on the PET component of 153 
PET/CT examinations(16).   154 
The potential prognostic value of CTTA in NSCLC was first reported in 2012 (17) but as yet 155 
this finding has not been translated into a widely adopted clinical application. It has been 156 
proposed that the prognostic information afforded by CTTA could be used to identify 157 
patients with a greater risk for post-surgical recurrence who might benefit most from 158 
adjuvant chemotherapy, or to recognise those patients with advanced disease who are 159 
unlikely to get sufficient survival benefit to justify the morbidity of chemotherapy in a 160 
palliative setting (2). However, the use of CT as a prognostic biomarker represents a novel 161 
application for imaging in the management of NSCLC, and in cancer care in general; a fact 162 
that may represent a block to the adoption of CTTA into clinical practice. On the other hand, 163 
the use of CT markers to assess risk of mediastinal malignancy is embedded within the 164 
current clinical guidelines published by NICE. The replacement of measurements of 165 
mediastinal nodal size by CTTA measurements of tumour heterogeneity would simply 166 
represent a development of an established concept and may therefore be more readily 167 
adopted into clinical practice.   168 
In summary, CTTA in NSCLC is related to nodal status in patients without distant 169 
metastases and has the potential to inform selection of investigative strategies for 170 
the assessment of mediastinal malignancy. 171 
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FIGURES  AND TABLES  224 
Figure 1. A: Axial CT image from a patient with a left upper lobe NSCLC categorised as high 225 
risk by CTTA using the filtration-histogram approach. B: Tumour ROI after filtration to 226 
highlight image features of radius 4mm. All three CT texture parameters derived from the 227 
histogram of values in filtered ROI (C) indicated increased risk for nodal disease: 4.74, 0.73 228 
and -0.09 for normalised SD, normalised E and kurtosis respectively. Maximum intensity 229 
projections (D) and fused axial images (E) from the patient’s PET/CT examination, which 230 
showed no nodal disease. N2 disease was confirmed at surgery. 231 
 232 
Figure 2. A: Axial CT image from a patient with a right upper lobe NSCLC categorised as low 233 
risk by CTTA using the filtration-histogram approach. B: Tumour ROI after filtration to 234 
highlight image features of radius 4mm. All three CT texture parameters derived from the 235 
histogram of values in the filtered ROI (C) indicated a reduced risk for nodal disease: 8.61, 236 
0.85 and -0.86 for normalised SD, normalised E and kurtosis respectively. The largest 237 
mediastinal node measured 11mm on CT (D), indicating a high risk of mediastinal malignancy 238 
according to NICE guidance. N0 disease was confirmed at surgery. 239 
 240 
Figure 3: The survival curve for patients with less than two high-risk CTTA values (above) 241 
showed no deaths in the follow-up period, compared to five deaths for patients with 2 or 242 
more high-risk CTTA values (below; p=0.016). 243 
 244 
Figure 4: Diagrammatic representation of how genetic instability can lead to genetically 245 
distinct subclones within a tumour, which express different phenotypes that lead to imaging 246 
heterogeneity. This in turn can be assessed quantitatively with CT Texture analysis 247 
 248 
Table 1. Risk of advancing N-stage for patients categorised by the median texture values 249 
with mediastinal nodal size at CT as comparator. 250 
 251 
Figure 1 Click here to download Figure Figure 1 final.tiff 
Figure 2 Click here to download Figure Figure 2 final.tiff 
Figure 3 Click here to download Figure Figure 3.tiff 
Figure 4 Click here to download Figure Figure 4 final.tiff 
Nodal 
Status 
Parameter High Risk Low  Risk Risk Ratio (95% CI) p-value 
(Fisher’s test) 
>0 Normalised SD 52.4% 23.8% 2.2 (95% CI 0.92-5.24) 0.11 
Normalised E 61.9% 14.3% 4.3 (95% CI 1.44 -13.0) 0.0036 
Kurtosis 57.1% 19.1% 3.0 (95% CI 1.15-7.80) 0.25 
Any 2 CTTA 61.9% 14.3% 4.3 (95% CI 1.44 -13.0) 0.0036 
Nodal size on CT 54.6% 32.3% 1.69(95% CI 0.80-3.55) 0.28 
>1 Normalised SD 42.9% 14.3% 3.0 (95% 0.94-9.55) 0.086 
Normalised E 47.6% 9.5% 5.0 (95% 1.24-20.1) 0.015 
Kurtosis 47.6% 9.5% 5.0 (95% 1.24-20.1) 0.015 
Any 2 CTTA 52.4% 4.76% 11.0 (95% CI 1.56 - 
77.8) 
0.0014 
Nodal size on CT 54.6% 19.4% 2.82 (95% CI 1.15 – 6.9) 0.049 
>2 Normalised SD 19.1% 0% ∞ 0.11 
Normalised E 14.3% 4.8% 3.0 (95% 0.34-26.6) 0.61 
Kurtosis 19.1% 0% ∞ 0.11 
Any 2 CTTA 19.1% 0% ∞ 0.11 






 CT texture analysis (CTTA) is emerging as a technique for derivation of 
prognostic biomarkers for patients with NSCLC  
 CT texture analysis evaluates quantitatively tumour heterogeneity, which is linked to 
tumour aggression. 
 CTTA  in NSCLC is related to nodal status in patients without distal metastases 
and has potential to inform selection of investigative strategies for the 
assessment of mediastinal malignancy. 
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